SPRAVATO™ (Esketamine) is a revolutionary FDA-approved treatment that has provided relief to thousands of individuals suffering from treatment-resistant depression. Unlike traditional antidepressants, such as SSRIs Fluoxetine (Prozac) or Sertraline (Zoloft), which target specific neurotransmitters like serotonin, SPRAVATO™ focuses on the NMDA receptor within nerve cells, helping to reset these connections and facilitate lasting relief. Administered as a nasal spray under the supervision of a certified healthcare provider, this groundbreaking therapy has the potential to alleviate depressive symptoms within hours, offering a novel approach and newfound hope for those who have struggled to find relief through conventional treatments. The rapid onset of action, coupled with its unique mechanism, makes SPRAVATO™ an innovative solution in the field of depression treatment, transforming the lives of countless individuals.